Development of a Doxazosin and Finasteride Transdermal System for Combination Therapy of Benign Prostatic Hyperplasia

摘要: The treatment of benign prostatic hyperplasia can be accomplished by the use different drugs including, doxazosin, an α-1 adrenergic antagonist, and finasteride (FIN), a 5-α reductase inhibitor. Traditionally, treatments using these have been administered as either mono or combination therapy oral route. A transdermal delivery system optimized for doxazosin FIN would provide increased patient adherence facilitate dose adjustment. Doxazosin base (DB) was prepared from mesylate characterized together with FIN, X-ray powder diffraction (XRD), differential scanning calorimetry (DSC), nuclear magnetic resonance (NMR). permeation enhancers, azone lauric acid, gelling agents, hydroxypropyl cellulose (HPC) Poloxamer 407 (P407), were evaluated to determine their ability promote in vitro through pig ear epidermis. Successful preparation DB confirmed evaluating XRD, DSC, NMR patterns studies revealed that 3% (w/w) best enhancer. When P407 gel compared HPC gel, it showed reduced lag time promoted higher both drugs. This may because interactions former stratum corneum, which disorganizes lipid structure consequently promotes drug permeation. © 2013 Wiley Periodicals, Inc. American Pharmacists Association J Pharm Sci 102:4057–4064,